
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for patients with sensitizing EGFR mutation-positive non-small cell lung cancer (NSCLC). Pivotal studies on first-generation EGFR TKIsgefitinib and erlotinib have confirmed improvement in progression-free survival (PFS) and objective response rate (ORR) but failed to demonstrate a statistically significant overall survival (OS) benefit over chemotherapy in patients with EGFR mutation-positive advanced NSCLC.
Like
Save
Share